Please assess the completion status of the following clinical trial:

Trial Title: Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Subject inclusion criteria~1. DSM IV-TR Bipolar I or II or Bipolar NOS Disorder~2. Ability to provide written informed consent~3. Male or Female patients, all races, ages 18 to 65 years inclusive~4. Negative serum pregnancy test for females of child-bearing potential. Patients must agree to one of the following birth control methods: an oral contraceptive agent, an intrauterine device (IUD), an implantable contraceptive (e.g., Norplant), or an injectable contraceptive (e.g., Depo Provera) for at least 1 month prior to entering the study and will continue its use through at least 30 days after the last dose of study medication or a barrier method of contraception, e.g., condom and/or diaphragm with spermicide while participating in the study through at least 30 days after the last dose of study medication or abstinence.~5. MADRS total scores ≤ 8 (past 4 weeks) (suicidal item, score ≤ 1, past 4 weeks).~6. Y-MRS scores ≤ 8 (past 4 weeks) irritability, speech content, disruptive, or aggressive behavior items score ≤ 3, past 4 weeks)~7. Stable doses of primary bipolar maintenance medication for at least 8 weeks prior to randomization~8. No psychiatric hospitalization or Emergency Room Visits for psychiatric issues in the 6-month period prior to randomization~9. No suicidal attempts or behavior history past 6 months~10. No aggressive or violent acts or behavior by history past 6 months~Subject exclusion criteria~1. Uncontrolled seizure disorders and other neurological disorders including Huntington's Chorea, Multiple Sclerosis, Cerebral Palsy, and stroke (cerebrovascular accident, CVA).~2. Current alcohol or other substance abuse or dependence within the last 3 months (caffeine will be permitted, nicotine dependence is part of inclusion criteria), including a case-by-case evaluation of those who meet remission criteria and who are on long-term substance abuse and/or alcohol abuse treatment.~3. Female patients who are pregnant, lactating or likely to become pregnant in next 6 months~4. Uncontrolled diabetes mellitus, asthma, seizure disorder, uncontrolled hypertension, (uncontrolled hypertension is defined as Systolic BP \> 150 mm or Hg or diastolic BP \> 95 mm or Hg on 2 consecutive BP readings 15 minutes apart at the time of screening) or unstable medical illness. Moderate to severe renal disease - moderate renal failure is defined as serum Creatinine \>1.3 mg/dl in women and \> 1.5 mg/dl in men, at the time of screening.~5. Severe dizziness or fainting due to orthostatic blood pressure changes~6. Known hypersensitivity to varenicline~7. Current use of cimetidine~8. Current treatment with heparin, warfarin, or lidocaine~9. Comorbid psychiatric condition diagnosed within the last three months.~Subject smoking inclusion criteria~1. Score of 7 or greater on the Contemplation Ladder, and willing to pick a target quit date within the next 4 weeks.~2. Smoke \> 10 cigarettes per day.~3. Expired breath CO level \> 10 ppm at screening and randomization.~4. No use of smoking cessation medication and/or behavioral treatment for smoking cessation in the past three months.~5. No current use of any nicotine replacement treatment.~6. Not using any tobacco products other than cigarettes.~7. No current treatment for smoking cessation (hypnosis, acupuncture, others).~8. No current use or past treatment failure with varenicline.~9. No current treatment with bupropion for smoking cessation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: EXPERIMENTAL): We will be comparing Varenicline to placebo in a double-blind placebo controlled, randomized study.
- Placebo (Type: PLACEBO_COMPARATOR): We will be using placebo in a randomized, controlled, and blinded trial to compare to varenicline in subjects with bipolar disorder.

Based on this trial design, predict the completion outcome and termination type (if applicable).